Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study)

被引:4
|
作者
Kamiya, Koji [1 ]
Saeki, Hidehisa [2 ]
Tokura, Yoshiki [3 ,4 ]
Yoshihara, Shigemi [5 ]
Sugai, Junichi [6 ]
Ohtsuki, Mamitaro [1 ]
机构
[1] Jichi Med Univ, Dept Dermatol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
[2] Nippon Med Sch, Dept Dermatol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
[3] Chutoen Gen Med Ctr, Allerg Dis Res Ctr, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[4] Chutoen Gen Med Ctr, Dept Dermatol & Skin Oncol, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[5] Dokkyo Med Univ, Dept Pediat, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan
[6] Sugai Dermatol Parkside Clin, 6-7-7 Motoimaizumi, Utsunomiya, Tochigi 3210954, Japan
关键词
atopic dermatitis; pediatric; proactive therapy; rank-down therapy; topical corticosteroids; FLUTICASONE PROPIONATE CREAM; DOUBLE-BLIND; GUIDELINES; MANAGEMENT; RELAPSE; EMOLLIENT; CHILDREN; MODERATE; RISK; 0.05-PERCENT;
D O I
10.3390/jcm11216477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Topical corticosteroids are used as first-line treatment for atopic dermatitis (AD). Regarding the maintenance of remission achieved by topical corticosteroids, no previous studies have compared proactive therapy with rank-down therapy. We compared their efficacy and safety in Japanese children with moderate to severe AD. Patients who had achieved remission with a very strong topical corticosteroid were randomized to 4-week maintenance treatment with either intermittent use of the same drug (proactive therapy) or daily use of a strong topical corticosteroid for 1 week followed by daily use of a medium-potency topical corticosteroid for 3 weeks (rank-down therapy); 49 patients were randomized (proactive therapy, n = 24; rank-down therapy, n = 25). During maintenance treatment, the relapse rate was 8.33% in the proactive therapy group and 20.0% in the rank-down therapy group (p = 0.0859). The mean (+/- standard deviation) itching score on a numerical rating scale in the rank-down therapy group increased significantly from 2.5 +/- 1.9 to 3.6 +/- 2.6 (p = 0.0438). Adverse events occurred in 2 patients receiving proactive therapy and 3 patients receiving rank-down therapy. Proactive therapy appears to be as safe as rank-down therapy and may be more effective for itch in pediatric AD in remission.
引用
收藏
页数:11
相关论文
共 45 条
  • [1] An Open-Label Prospective Study to Compare the Efficacy and Safety of Topical Fluticasone Versus Tacrolimus in the Proactive Treatment of Atopic Dermatitis
    Mudaliyar, Vinodhini R.
    Pathak, Asha
    Dixit, Alok
    Kumar, Sweta S.
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2020, 10 (04):
  • [2] Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial
    Mori, Masaaki
    Hara, Takuma
    Kikuchi, Masako
    Shimizu, Hiroyuki
    Miyamoto, Tomoyuki
    Iwashima, Satoru
    Oonishi, Tatsuya
    Hashimoto, Kunio
    Kobayashi, Norimoto
    Waki, Kenji
    Suzuki, Yasuo
    Otsubo, Yoshikazu
    Yamada, Hiroshi
    Ishikawa, Chikao
    Kato, Taichi
    Fuse, Shigeto
    SCIENTIFIC REPORTS, 2018, 8
  • [3] Efficacy and Tolerability of a Medical Device Repairing Emollient Cream Associated with a Topical Corticosteroid in Adults with Atopic Dermatitis: An Open-label, Intra-individual Randomized Controlled Study
    Rossi, Ana Beatris
    Bacquey, Adeline
    Nocera, Therese
    Thouvenin, Marie-Dominique
    DERMATOLOGY AND THERAPY, 2018, 8 (02) : 217 - 228
  • [4] Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study
    Lee, Kyung-Hee
    Kang, Jung-Hun
    Oh, Ho-Suk
    Choi, Moon-Ki
    Shim, Byoung-Yong
    Eum, Young-Jun
    Park, Hye-Jeong
    Kang, Jin-Hyong
    PAIN RESEARCH & MANAGEMENT, 2017, 2017
  • [5] INTERMITTENT PROACTIVE MAINTENANCE TREATMENT WITH 0.03% TACROLIMUS OINTMENT IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS: RESULTS FROM A MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY
    Liu, Lingling
    Zhu, Xuejun
    Zhao, Zuotao
    Wang, Shan
    Ma, Lin
    Gu, Heng
    Wang, Hua
    Chen, Jinping
    Yao, Zhirong
    Chen, Ji
    JOURNAL OF DERMATOLOGY, 2014, 41 : 10 - 10
  • [6] Efficacy and Tolerability of a Medical Device Repairing Emollient Cream Associated with a Topical Corticosteroid in Adults with Atopic Dermatitis: An Open-label, Intra-individual Randomized Controlled Study
    Ana Beatris Rossi
    Adeline Bacquey
    Thérèse Nocera
    Marie-Dominique Thouvenin
    Dermatology and Therapy, 2018, 8 : 217 - 228
  • [7] Comparing emollient use with topical luliconazole (azole) in the maintenance of remission of chronic and recurrent dermatophytosis. An open-label, randomized prospective active-controlled non-inferiority study
    Pathania, Yashdeep Singh
    Katoch, C. D. S.
    Kumar, Ashok
    MYCOSES, 2024, 67 (01)
  • [8] Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
    Ferrannini, Ele
    Berk, Andreas
    Hantel, Stefan
    Pinnetti, Sabine
    Hach, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES CARE, 2013, 36 (12) : 4015 - 4021
  • [9] Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study
    Nakagawa, Hidemi
    Nemoto, Osamu
    Igarashi, Atsuyuki
    Saeki, Hidehisa
    Kabashima, Kenji
    Oda, Manabu
    Nagata, Takeshi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (04) : 854 - 862
  • [10] Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study
    Kawashima, M
    Tango, T
    Noguchi, T
    Inagi, M
    Nakagawa, H
    Harada, S
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (06) : 1212 - 1221